RT Journal Article
T1 Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life.
A1 Real, Luis M
A1 Macias, Juan
A1 Perez, Ana B
A1 Merino, Dolores
A1 Granados, Rafael
A1 Morano, Luis
A1 Delgado, Marcial
A1 Rios, Maria J
A1 Galera, Carlos
A1 Deltoro, Miguel G
A1 Merchante, Nicolas
A1 Garcia, Federico
A1 Pineda, Juan A
K1 Área de Gestión Sanitaria Sur de Sevilla
K1 Middle Aged
K1 Sustained Virologic Response
K1 Viral Nonstructural Proteins
AB Hepatitis C virus (HCV) response to direct-acting antivirals (DAAs) may be influenced by the presence of resistance-associated substitutions (RASs). This study aimed to assess if NS5A baseline RAS-guided treatment enhances the rate of sustained viral response (SVR) in naïve HCV-infected patients in clinical practice. All HCV-infected patients who initiated treatment with interferon (IFN)-free DAA-based regimens between March 2016 and May 2017 in 17 Spanish hospitals and who had evaluable SVR 12 weeks (SVR12) after the end of therapy were included. Patients had to be DAA naïve, with the exception of sofosbuvir with/without IFN. In one hospital, participants received therapy guided by the presence of NS5A-RASs (RGT population). Patients enrolled in the remaining hospitals, without baseline RASs testing, constituted the control population. A total of 120 and 512 patients were included in the RGT and control populations, respectively. Nine (7.5%) individuals in the RGT population showed baseline NS5A-RASs. All of them achieved SVR12. The SVR12 rate in the RGT population was 97.2% (three relapses) whereas it was 98.8% (six relapses) in the control population (p = 0.382). Our findings suggest that testing for baseline NS5A-RASs in naïve HCV-infected patients does not enhance the rate of SVR to DAA-based IFN-free therapy in clinical practice.
PB Nature Publishing Group
YR 2018
FD 2018-10-08
LK http://hdl.handle.net/10668/13046
UL http://hdl.handle.net/10668/13046
LA en
NO Real LM, Macías J, Pérez AB, Merino D, Granados R, Morano L, et al. Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life. Sci Rep. 2018 Oct 8;8(1):14905
NO This work was supported in part by grants from the Fondo de Investigación Sanitaria (www.isciii.es) (PI15/00713), Plan Nacional de I+D+I and cofinanced by ISCIII-Subdirección General de Evaluación, the Fondo Europeo de Desarrollo Regional (FEDER) (www.red.es/redes/inicio) (RD16/0025/0040 and RD12/0017/0012), Fundación Progreso y Salud de la Junta de Andalucía (PI-0411-2014 and PI-0001/2017), and GEHEP-SEIMC (GEHEP004). J.A.P. has received a research extension grant from the Programa de Intensificación de la Actividad de Investigación del Servicio Nacional de Salud Carlos III (I3SNS). F.G. has received a research extension grant from the Programa de Intensificación de la Actividad de Investigación del Servicio Andaluz de Salud. J.M. and L.M.R. are the recipients of grants from the Servicio Andaluz de Salud de la Junta de Andalucía (B-0037 and C-0009-2015, respectively).
DS RISalud
RD Apr 5, 2025